Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar 10;16(3):e0248408.
doi: 10.1371/journal.pone.0248408. eCollection 2021.

Challenging drug-resistant TB treatment journey for children, adolescents and their care-givers: A qualitative study

Mrinalini Das  1   2 , Taanya Mathur  1 , Shilpa Ravi  1 , Augusto C Meneguim  1 , Aparna Iyer  1 , Homa Mansoor  1 , Stobdan Kalon  1 , Farah Naz Hossain  1 , Shrikala Acharya  3 , Gabriella Ferlazzo  4 , Petros Isaakidis  4 , Harshad P Thakur  2   5
Affiliations
Clinical Trial

Challenging drug-resistant TB treatment journey for children, adolescents and their care-givers: A qualitative study

Mrinalini Das et al. PLoS One. .

Erratum in

Abstract

Background: Childhood multidrug-resistant TB (MDR-TB) still affects around 25000 children every year across the globe. Though the treatment success rates for drug-resistant TB (DR-TB) in children are better than adults, children and adolescents face unique hurdles during DR-TB (MDR-TB, Pre-XDR TB and XDR-TB) treatment. This study aimed to understand the patients, guardians and healthcare providers' perspectives about DR-TB treatment journey of patients and caregivers.

Methods: This is a qualitative study involving in depth-interviews of purposively selected adolescents (n = 6), patients guardians (for children and adolescents, n = 5) and health care providers (n = 8) of Médecins Sans Frontières (MSF) clinic, Mumbai, India. In-depth face to face interviews were conducted in English or Hindi language using interview guides during September-November 2019. The interviews were audio-recorded after consent. Thematic network analysis was used to summarize textual data. ATLAS.ti (version 7) was used for analysis.

Result: The age of adolescent patients ranged from 15-19 years and four were female. Five guardians (of three child and two adolescent patients) and eight healthcare providers (including clinicians- 2, DOT providers-2, counselors-2 and programme managers-2) were interviewed. The overarching theme of the analysis was: Challenging DR-TB treatment journey which consisted of four sub-themes: 1) physical-trauma, 2) emotional-trauma, 3) unavailable social-support and 4) non-adapted healthcare services. Difficulties in compounding of drugs were noted for children while adolescents shared experiences around disruption in social life due to disease and treatment. Most of the patients and caregivers experienced treatment fatigue and burnout during the DR-TB treatment. Participants during interviews gave recommendations to improve care.

Discussion: The TB programmes must consider the patient and family as one unit when designing the package of care for paediatric DR-TB. Child and adolescent friendly services (paediatric-formulations, age-specific counselling tools and regular interaction with patients and caregivers) will help minimizing burnout in patients and caregivers.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Non-hierarchical thematic network for ‘challenging DR-TB treatment journey’ in children and adolescents, Mumbai, India, 2019.
Fig 2
Fig 2. Factors of treatment fatigue and burnout in children and adolescents with DR-TB and their caregivers, Mumbai, India, 2019.
See this image and copyright information in PMC

References

    1. Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int. J. Tuberc. Lung Dis. 2018;22:3–6. 10.5588/ijtld.17.0357 - DOI - PMC - PubMed
    1. Brigden G, Furin J, Van Gulik C, Marais B. Getting it right for children: Improving tuberculosis treatment access and new treatment options. Expert Rev. Anti. Infect. Ther. 2015;13:451–61. 10.1586/14787210.2015.1015991 - DOI - PubMed
    1. Furin J, Mafukidze A, Brigden G, Du Cros P, Golin R, Harausz E, et al.. A bitter pill to swallow: The need for better medications for drugresistant tuberculosis in children. Int. J. Tuberc. Lung Dis. 2015;19:S55–60. - PubMed
    1. World Health Organization (WHO). Roadmap for childhood tuberculosis. 2013;44.
    1. Marais BJ. Newer Drugs for Tuberculosis Prevention and Treatment in Children. Indian J. Pediatr. 2019;86:725–31. 10.1007/s12098-018-02854-8 - DOI - PubMed

Substances